Intravitreal injections are a crucial treatment modality in ophthalmology, primarily used to deliver medications directly into the vitreous cavity of the eye. This technique is particularly effective in managing various sight-threatening conditions such as age-related macular degeneration (AMD), diabetic retinopathy, and macular edema. By bypassing the blood-retinal barrier, intravitreal injections ensure high concentrations of medications reach the target site, maximizing therapeutic efficacy while minimizing systemic side effects.
Common medications administered via intravitreal injection include anti-vascular endothelial growth factor (anti-VEGF) agents like ranibizumab and aflibercept, which help inhibit abnormal blood vessel growth and reduce fluid leakage in the retina. Corticosteroids such as dexamethasone implants are also used to suppress inflammation and edema. While generally safe, intravitreal injections carry risks of complications such as infection, retinal detachment, or intraocular pressure elevation, necessitating careful patient monitoring. Overall, these injections represent a pivotal advancement in managing retinal diseases, offering many patients significant visual improvement and preservation.
Objective : To investigate the effect of intravitreal implant of ranibizumab combined with dexamethasone on Vascular Endothelial Growth Factors (VEGFs), Interleukins (ILs) and clinical efficacy in…
Modern Anti–Vascular Endothelial Growth Factor (VEGF) agents, including aflibercept 8 mg (Eylea HD) and Faricimab (Vabysmo), have shown promise in extending treatment intervals while maintaining or…
Background: Laser photocoagulation and/or intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections constitute the current standard treatment for retinopathy of prematurity (ROP).…
Background : Intravitreal injection (IVI) therapy used in the management of exudative retinal diseases has expanded significantly following the introduction of anti-vascular endothelial growth factor…
Sessions are CPD-accredited by The CPD Group (UK) — one CPD credit for every hour of attendance.
Oral and poster slots for original Intravitreal Injections work, reviewed by the scientific committee.
Meet ophthalmologists, vision scientists, and eye-care clinicians from around the world across three days.
Accepted abstracts are compiled into the conference proceedings and indexed in Scopus and Web of Science.
Plenary lectures from leading voices shaping Intravitreal Injections research and practice.
Attend in person in Singapore or join virtually — same programme, same certificate.
Oral and poster slots for your work — in person in Singapore or online. Not presenting? Attend as a delegate to learn from the field.
The Intravitreal Injections track is a dedicated stream within IOC 2027 covering the latest research, clinical innovation, and best practice in Intravitreal Injections. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Ophthalmologists, optometrists, vision scientists, educators, doctoral students, and trainees with an interest in Intravitreal Injections are all welcome — whether presenting or attending.
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Yes. IOC 2027 is a hybrid conference — attend the Intravitreal Injections track in person in Singapore or join live online, with on-demand access afterward.
Singapore · March 15–17, 2027· Hybrid · in-person & virtual
Attend without presenting.
